1. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Issue 2 (February 2022) Authors: Kaddu-Mulindwa, Dominic; Altmann, Bettina; Robrecht, Sandra; Ziepert, Marita; Regitz, Evi; Tausch, Eugen; Held, Gerhard; Poeschel, Viola; Lesan, Vadim; Bittenbring, Joerg Thomas; Thurner, Lorenz; Pfreundschuh, Michael; Christofyllakis, Konstantinos; Truemper, Lorenz; Loeffler, Markus; Schmitz, No... Journal: Lancet Issue: Volume 9:Issue 2(2022) Page Start: e133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗